Drug General Information (ID: DDIL0A9ZTK)
Drug Name			Ioxilan		Drug Info		Tyropanoic acid		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Non-Ionic Iodinated Contrast Media				Diagnostic Radiopharmaceuticals
Structure

Mechanism of Ioxilan-Tyropanoic acid Interaction (Severity Level: Moderate)
Increased risk of nephrotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Ioxilan				Tyropanoic acid
Mechanism		Nephrotoxicity				Nephrotoxicity
Key Mechanism Factor 1
		Factor Name		Nephrotoxicity
		Factor Description		The combination of drugs that can induce nephrotoxicity may increase the risk of kidney injury. When kidney injury occurs, the inability to remove excess urine and waste from the body can lead to high levels of urea nitrogen, creatinine, and electrolytes (such as potassium and magnesium) in the blood.
Mechanism Description		Increased risk of nephrotoxicity by the combination of Ioxilan and Tyropanoic acid

Recommended Action
Management		Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.

References
1	Product Information. Ultravist (iopromide). Berlex, Richmond, CA.
2	Product Information. Visipaque (iodixanol). Nycomed Inc, Princeton, NJ.
3	Product Information. Omniscan (gadodiamide). Novation, Irving, TX.